ALTAMURA, CONCETTA
 Distribuzione geografica
Continente #
NA - Nord America 1.133
EU - Europa 410
AS - Asia 66
Totale 1.609
Nazione #
US - Stati Uniti d'America 1.132
DE - Germania 108
SE - Svezia 103
IT - Italia 83
CN - Cina 51
RU - Federazione Russa 42
GB - Regno Unito 32
FR - Francia 14
VN - Vietnam 10
BE - Belgio 9
FI - Finlandia 9
UA - Ucraina 5
TR - Turchia 3
NL - Olanda 2
AT - Austria 1
CR - Costa Rica 1
HU - Ungheria 1
ID - Indonesia 1
IE - Irlanda 1
PH - Filippine 1
Totale 1.609
Città #
Fairfield 202
Chandler 133
Houston 108
Woodbridge 106
Ashburn 87
Nyköping 86
Cambridge 68
Wilmington 57
Seattle 54
Ann Arbor 52
Bari 34
Roxbury 22
Beijing 20
Lawrence 20
Inglewood 19
Des Moines 17
Jacksonville 17
San Diego 14
Nanjing 13
Dong Ket 10
Paris 9
Brussels 7
Montignoso 6
Princeton 6
Brooklyn 5
Dearborn 4
London 4
Mottola 4
Nanchang 4
Los Angeles 3
Boardman 2
Chicago 2
Esslingen am Neckar 2
Florence 2
Guangzhou 2
Hebei 2
Helsinki 2
Jiaxing 2
Magliano Alpi 2
Milan 2
Perugia 2
Redwood City 2
Rome 2
San Mateo 2
Shenyang 2
Taranto 2
Tianjin 2
Vinovo 2
Waanrode 2
Acquaviva delle Fonti 1
Andria 1
Augusta 1
Castelnuovo Rangone 1
Changsha 1
Denver 1
Dublin 1
Fasano 1
Fort Worth 1
Giresun 1
Gravina In Puglia 1
Jinan 1
Krasnoyarsk 1
Kunming 1
Leawood 1
Makati 1
Marseille 1
Martina Franca 1
Miami 1
Modugno 1
Monmouth Junction 1
Nettuno 1
Padova 1
Reston 1
San Francisco 1
San José 1
Seelze 1
Settingiano 1
Simi Valley 1
Tappahannock 1
Vicenza 1
Vienna 1
Totale 1.261
Nome #
Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies 151
ClC-1 chloride channels: state-of-the-art research and future challenges 149
Mapping ligand binding pockets in ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid 128
Clinical, Molecular, and Functional Characterization of CLCN1 Mutations in Three Families with Recessive Myotonia Congenita 124
The analysis of myotonia congenita mutations discloses functional clusters of amino acids within CBS2 domain and C-terminal peptide of ClC-1 channel 106
ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation 104
Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia 100
Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate 98
Effects of Benzothiazolamines on Voltage-Gated Sodium Channels 89
A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions 88
Ion channels gene expression analysis in myotonia congenita patients carrying ClC-1 chloride channel mutations 64
Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo 57
Skeletal muscle ClC-1 chloride channels in health and diseases 50
Synthesis and Evaluation of Voltage-Gated Sodium Channel Blocking Pyrroline Derivatives Endowed with Both Antiarrhythmic and Antioxidant Activities 46
Pathomechanisms of a CLCN1 Mutation Found in a Russian Family Suffering From Becker's Myotonia 42
Natural ClC-1 mutations causing myotonia congenita reduce sensitivity to 9-AC 35
Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine 33
Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in KCNA1 Impairing the Voltage Sensitivity of Kv1.1 Channel 32
Emerging roles for ion channels in ovarian cancer: Pathomechanisms and pharmacological treatment 32
Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels 32
null 29
Buprenorphine may be effective for treatment of paramyotonia congenita 26
Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders 24
Privileged scaffold-based design to identify a novel drug-like 5-HT7 receptor-preferring agonist to target Fragile X syndrome 23
Ion Channel Gene Mutations Causing Skeletal Muscle Disorders: Pathomechanisms and Opportunities for Therapy 22
Ion Channel Involvement in Tumor Drug Resistance 18
Chaperone activity of niflumic acid on ClC-1 chloride channel mutants causing myotonia congenita 14
Drug repurposing in skeletal muscle ion channelopathies 6
Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives 6
Target mutation-driven drug discovery 5
Coexistence of SCN4A and CLCN1 mutations in a family with atypical myotonic features: A clinical and functional study 3
Immersive and Non-Immersive Virtual Reality for Pain and Anxiety Management in Pediatric Patients with Hematological or Solid Cancer: A Systematic Review 3
Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications 3
Anti-Angiogenic Activity of Drugs in Multiple Myeloma 3
Totale 1.745
Categoria #
all - tutte 5.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.666


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019188 0 0 12 0 7 10 1 7 18 24 58 51
2019/2020314 46 12 21 39 24 21 22 25 27 33 35 9
2020/2021436 33 25 32 48 31 42 47 20 31 64 32 31
2021/2022232 16 15 5 20 2 14 4 10 15 40 41 50
2022/2023359 33 54 33 17 24 52 11 57 45 10 16 7
2023/202446 8 31 7 0 0 0 0 0 0 0 0 0
Totale 1.745